DcpS as a therapeutic target for spinal muscular atrophy.
DcpS as a therapeutic target for spinal muscular atrophy.
复制标题
DOI:
10.1021/cb800120t
复制
发表时间:
2008-11-21
影响因子:
4
通讯作者:
Gurney ME
中科院分区:
文献类型:
--
作者:
Singh J;Salcius M;Liu SW;Staker BL;Mishra R;Thurmond J;Michaud G;Mattoon DR;Printen J;Christensen J;Bjornsson JM;Pollok BA;Kiledjian M;Stewart L;Jarecki J;Gurney ME
Spinal muscular atrophy (SMA) is caused by deletion or mutation of both copies of the SMN1 gene which produces an essential protein known as SMN. The severity of SMA is modified by variable copy number of a second gene, SMN2 that produces an mRNA that is incorrectly spliced with deletion of the last exon. We described previously the discovery of potent C5-substituted quinazolines that increase SMN2 gene expression by two-fold. Discovery of potent SMN2 promoter inducers relied on a cellular assay without knowledge of the molecular target. Using protein microarray scanning with a radiolabeled C5-quinazoline probe, we identified the scavenger decapping enzyme, DcpS as a potential binder. We show that the C5-quinazolines potently inhibit DcpS decapping activity, and that the potency of inhibition correlates with potency for SMN2 promoter induction. Binding of C5-quinazolines to DcpS holds the enzyme in an open, catalytically incompetent conformation. DcpS is a nuclear shuttling protein that binds and hydrolyzes the m7GpppN mRNA cap structure and a modulator of RNA metabolism. Therefore DcpS represents a novel therapeutic target for modulating gene expression by a small molecule.
登录
查看更多内容
影响因子:
64.5
作者:
LEFEBVRE, S;BURGLEN, L;MELKI, J
通讯作者:
MELKI, J
影响因子:
4.8
作者:
TOMONAGA, T;LEVENS, D
通讯作者:
LEVENS, D
影响因子:
4.4
作者:
Gao, CJ;Guo, HT;Kuo, PC
通讯作者:
Kuo, PC
影响因子:
4.5
作者:
Liu, SW;Jiao, XF;Kiledjian, M
通讯作者:
Kiledjian, M
DOI:
10.1107/s0907444904019158
发表时间:
2004-12-01
影响因子:
2.2
作者:
Emsley, P;Cowtan, K
通讯作者:
Cowtan, K